With regard to the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 (the Interim Order) on September 16, 2020: (a) does the Minister of Health require an application by the manufacturer to approve a drug that is already approved for another indication; (b) what is the total number of inquiries received by Health Canada and the Public Health Agency of Canada about Ivermectin for the prophylaxis and treatment of COVID- 19; (c) how many inquiries have been made to Health Canada and the Public Health Agency of Canada about Ivermectin for the prophylaxis and treatment of COVID-19, broken down by (i) the general public (ii) healthcare clinicians, (iii) researchers, (iv) provincial and territorial health authorities, (v) hospitals, (vi) long-term care facilities, (vii) healthcare practitioners' regulatory governing bodies, (viii) Members of provincial, territorial and federal Parliament (ix) organizations; and (d) what is the number of signatures on any petitions related to Ivermectin?
In the House of Commons on January 29th, 2024. See this statement in context.